AcadeMab Biomedical and Academia Sinica enter into exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids

Academia Sinica and AcadeMab Biomedical have reached an exclusive licensing agreement. The project includes dengue fever mRNA vaccine and a series of novel cationic lipids. Under the terms of the agreement, AcadeMab will establish a new "mRNA Vaccine R&D Department" for the development, manufacturing of dengue mRNA vaccine and implementing pre-clinical and clinical trials as well as commercializing cationic lipids.

As the global dengue fever epidemic continues to rise, AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term. In addition, AcadeMab will leverage its cationic lipid platform to lower the barriers to developing mRNA delivery technology and help create an ecosystem for mRNA vaccine manufacturing.